Expression of Melan-A/MART-1 antigen as a prognostic factor in primary cutaneous melanoma

International Journal of Cancer

Volumn 95, Issue 1, 2001, Pages 73-77

  Berset, Magali ^a   Cerottini, Jean Philippe ^a   Guggisberg, David ^a   Romero, Pedro ^b   Burri, Franoise ^b   Rimoldi, Donata ^a,b   Panizzon, Renato G ^b  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

Melanoma; Monoclonal antibodies; Prognosis; Survival

Indexed keywords

MELAN A;

ARTICLE; CANCER STAGING; CANCER SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MELANOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

ANTIGENS, NEOPLASM; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MELANOMA; MULTIVARIATE ANALYSIS; NEOPLASM PROTEINS; PROGNOSIS; SKIN NEOPLASMS; TIME FACTORS;

EID: 0035915806     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0215(20010120)95:1<73::AID-IJC1013>3.0.CO;2-S     Document Type: Article

References (23)

1. Tumor thickness, level of invasion and node dissection in stage I cutaneous melanoma
2. Identifying predictive factors in melanoma progression
3. Skin melanoma in Italy: A population-based study on survival and prognostic factors
4. Predicting five-year outcome for patients with cutaneous melanoma in a population-based study
5. Prognostic value of biomarkers in malignant melanoma
6. p53-protein and Ki-67-antigen expression are both reliable biomarkers of prognosis in thick stage I nodular melanomas of the skin
7. MIB-1 proliferative activity is a significant prognostic factor in primary thick cutaneous melanomas
8. Human tumor antigens recognized by T lymphocytes
9. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas
10. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor
11. Serological analysis of Melan-A(MART-1), a melanocyte-specific protein homogeneously expressed in human melanomas
12. Production of recombinant MART-1 proteins and specific antiMART-1 polyclonal and monoclonal antibodies: Use in the characterization of the human melanoma antigen MART-1
13. Melan A/MART-1 immunoreactivity in formalin-fixed paraffin-embedded primary and metastatic melanoma: Frequency and distribution
14. A103: An anti-melan-a monoclonal antibody for the detection of malignant melanoma in paraffin-embedded tissues
15. High homogeneity of MAGE, BAGE, GAGE, tyrosinase and Melan-A/MART-1 gene expression in clusters of multiple simultaneous metastases of human melanoma: Implications for protocol design of therapeutic antigen-specific vaccination strategies
16. Immunocytochemical detection of MART - 1 in fresh and paraffin-embedded malignant melanomas
17. Comparison of immunohistochemical staining of the novel antibody melan-A with S100 protein and HMB-45 in malignant melanoma and melanoma variants
18. Differential expression of MART-1 in primary and metastatic melanoma lesions
19. Melan-A/MART-1 antigen expression in cutaneous and ocular melanomas
20. Melan-A, a new melanocytic differentiation marker
21. Heterogeneous expression of immunotherapy candidate proteins gp100, MART-1, and tyrosinase in human melanoma cell lines and in human melanocytic lesions
22. Immunoselection in vivo: Independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma
23. Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes